Global Pharmaceuticals & Healthcare Report Q4 2017
BMI View: Innovative pharmaceutical companies will be making more concessions to governments, health systems and large payers in emerging markets. As in developed states, these stakeholders have limited budgets but also want to widen access to the latest treatments. Drugmakers should view these new types of arrangements as opportunities and not revenue-limiting. Conversely, the governments, health systems and large payers should seek equitable measures, otherwise pharmaceutical companies will invest elsewhere or seek market access through less favourable approaches.